Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Pacira BioSciences Inc shares valued at $228,912 were purchased by Cross Shawn on Dec 10 ’25. At $25.14 per share, Cross Shawn acquired 9,104 shares.
Also, Cross Shawn purchased 15,896 shares, netting a total of over 397,837 in proceeds.
Before that, SLONIN JONATHAN had sold 3,960 shares from its account. In a trade valued at $95,396, the Chief Medical Officer traded Pacira BioSciences Inc shares for $24.09 each. Upon closing the transaction, the insider’s holdings decreased to 3,960 shares, worth approximately $4.49 million.
As published in their initiating research note from Barclays on December 09, 2025, Pacira BioSciences Inc [PCRX] has been an Equal weight and the price target has been revised to $27. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in mid November. As of July 25, 2025, Truist has increased its “Hold” rating to a “Buy” for PCRX. Earlier on January 30, 2025, Truist upgraded its rating. Their new recommendation was “a Hold” for PCRX stock which previously was a “a Sell”.
Analyzing PCRX Stock Performance
On last trading session, Pacira BioSciences Inc [NASDAQ: PCRX] rose 1.66% to $25.18. The stock’s lowest price that day was $24.55, but it reached a high of $25.32 in the same session. During the last five days, there has been a surge of approximately 4.09%. Over the course of the year, Pacira BioSciences Inc shares have jumped approximately 30.67%. Shares of the company reached a 52-week high of $27.64 on 09/03/25 and a 52-week low of $18.17 on 01/06/25.
Support And Resistance Levels for Pacira BioSciences Inc (PCRX)
According to the 24-hour chart, there is a support level at 24.71, which, if violated, would cause prices to drop to 24.25. In the upper region, resistance lies at 25.48. The next price resistance is at 25.79. RSI (Relative Strength Index) is 65.85 on the 14-day chart, showing neutral technical sentiment.
Is Pacira BioSciences Inc subject to short interest?
Stocks of Pacira BioSciences Inc saw a sharp steep in short interest on 2025-11-28 dropping by 61929.0 shares to 7.22 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 7.28 million shares. A decline of -0.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.67 of the overall float, the days-to-cover ratio (short ratio) decline to 9.67.
Which companies own the most shares of Pacira BioSciences Inc (PCRX)?
In terms of Pacira BioSciences Inc share price expectations, FactSet research, analysts set an average price target of 27 in the next 12 months, up nearly 9.0% from the previous closing price of $24.77. Analysts anticipate Pacira BioSciences Inc stock to reach 27 by 2025, with the lowest price target being 27. In spite of this, 6 analysts ranked Pacira BioSciences Inc stock as Buy at the end of 2025. On August 13, 2024, Truist assigned a price target of “a Sell” to the stock and downgraded coverage with a $8.
